{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:53:00Z","timestamp":1782924780830,"version":"3.54.5"},"reference-count":68,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Spanish MINISTERIO DE CIENCIA E INNOVACI\u00d3N","doi-asserted-by":"publisher","award":["PID2022-141783OB-C22\/AEI\/10.13039\/501100011033\/FEDER-UE"],"award-info":[{"award-number":["PID2022-141783OB-C22\/AEI\/10.13039\/501100011033\/FEDER-UE"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centro de Instrumentaci\u00f3n Cient\u00edfico-T\u00e9cnica (CICT) of the University of Ja\u00e9n, Spain","award":["PID2022-141783OB-C22\/AEI\/10.13039\/501100011033\/FEDER-UE"],"award-info":[{"award-number":["PID2022-141783OB-C22\/AEI\/10.13039\/501100011033\/FEDER-UE"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Human lactate dehydrogenase A (hLDHA) is a homotetrameric isozyme involved in the conversion of glyoxylate into oxalate in the cytosol of liver cells (hepatocytes) and partially responsible for the overproduction of oxalate in patients with the rare disease called primary hyperoxaluria (PH). Recently, hLDHA inhibition has been validated as a safe therapeutic method to try to control the PH disease. Stiripentol (STP) is an approved drug used in the treatment of seizures associated with Dravet\u2019s syndrome (a severe form of epilepsy in infancy) which, in addition, has been drawing interest in recent years also for potentially treating PH, due to its hLDHA inhibitory activity. In this work, several new STP-related compounds have been synthesized and their hLDHA inhibitory activity has been compared to that of STP. The synthesis of these analogues to STP was accomplished using crossed-aldol condensation guided by lithium enolate chemistry and a successive regioselective reduction of the resulting \u03b1,\u03b2-unsaturated ketones. The target molecules were obtained as racemates, which were separated into their enantiomers by chiral HPLC. The absolute configurations of pure enantiomers were determined by the modified Mosher\u2019s method and electronic circular dichroism (ECD) spectroscopy. For the inhibitory effect over the hLDHA catalytic activity, a kinetic spectrofluorometric assay was used. All the new synthesized compounds turned out to be more active at 500 \u03bcM (46\u201372% of inhibition percentage) than STP (10%), which opens a new line of study on the possible capacity of these analogues to reduce urinary oxalate levels in vivo more efficiently.<\/jats:p>","DOI":"10.3390\/ijms252413266","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T11:17:20Z","timestamp":1733829440000},"page":"13266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synthesis and hLDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2317-1685","authenticated-orcid":false,"given":"Mario","family":"Rico-Molina","sequence":"first","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Experimental Sciences, University of Ja\u00e9n, Campus of International Excellence in Agri-Food (ceiA3), 23071 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3244-3781","authenticated-orcid":false,"given":"Juan","family":"Ortega-Vidal","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Experimental Sciences, University of Ja\u00e9n, Campus of International Excellence in Agri-Food (ceiA3), 23071 Ja\u00e9n, Spain"},{"name":"School of Biological and Chemical Sciences, Ryan Institute, University of Galway, H91 TK33 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-1132","authenticated-orcid":false,"given":"Juan","family":"Molina-Canteras","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Experimental Sciences, University of Ja\u00e9n, Campus of International Excellence in Agri-Food (ceiA3), 23071 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-2390","authenticated-orcid":false,"given":"Justo","family":"Cobo","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Experimental Sciences, University of Ja\u00e9n, Campus of International Excellence in Agri-Food (ceiA3), 23071 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-8535","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Altarejos","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Experimental Sciences, University of Ja\u00e9n, Campus of International Excellence in Agri-Food (ceiA3), 23071 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-7873","authenticated-orcid":false,"given":"Sof\u00eda","family":"Salido","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Organic Chemistry, Faculty of Experimental Sciences, University of Ja\u00e9n, Campus of International Excellence in Agri-Food (ceiA3), 23071 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.seizure.2024.02.004","article-title":"Efficacy of pharmacological treatments for Dravet syndrome: Systematic review and network meta-analysis","volume":"117","author":"Xia","year":"2024","journal-title":"Seizure"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40265-019-01204-y","article-title":"Stiripentol: A review in Dravet syndrome","volume":"79","author":"Frampton","year":"2019","journal-title":"Drugs"},{"key":"ref_3","first-page":"543","article-title":"Les epilepsies graves de l\u2019enfant","volume":"8","author":"Dravet","year":"1978","journal-title":"Vie M\u00e9d."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fan, H.-C., Yang, M.-T., Lin, L.-C., Chiang, K.-L., and Chen, C.-M. (2024). Clinical and genetic features of Dravet syndrome: A prime example of the role of precision medicine in genetic epilepsy. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202311.1719.v1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107041","DOI":"10.1016\/j.eplepsyres.2022.107041","article-title":"Dravet syndrome: Advances in etiology, clinical presentation, and treatment","volume":"188","author":"He","year":"2022","journal-title":"Epilepsy Res."},{"key":"ref_6","unstructured":"Vallet, F.M.J. (1972). Anxiolytic and Muscle Relaxant 4,4-Dimethyl-1-(3,4-Methylenedioxyphenyl)-1-Pentenes. Patent FR2173691."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gao, C., Pielas, M., Jiao, F., Mei, D., Wang, X., Kotulska, K., and Jozwiak, S. (2023). Epilepsy in Dravet syndrome: Current and future therapeutic opportunities. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072532"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s12325-024-02813-0","article-title":"An update on stiripentol mechanisms of action: A narrative review","volume":"41","author":"Bacq","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/MNH.0000000000000987","article-title":"A molecular journey on the pathogenesis of primary hyperoxaluria","volume":"33","author":"Cellini","year":"2024","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41585-021-00543-4","article-title":"Perspectives in primary hyperoxaluria\u2014Historical, current and future clinical interventions","volume":"19","author":"Shee","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/ckj\/sfab245","article-title":"Primary hyperoxaluria type 1: Novel therapies at a glance","volume":"15","author":"Bacchetta","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00467-023-06200-9","article-title":"Clinical characteristics, genetic profile and short-term outcomes of children with primary hyperoxaluria type 2: A nationwide experience","volume":"39","author":"Krishnasamy","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/humu.24490","article-title":"HOGA1 gene pathogenic variants in primary hyperoxaluria type III: Spectrum of pathogenic sequence variants, and phenotypic association","volume":"43","author":"Abid","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s00467-024-06328-2","article-title":"Diagnosis and management of primary hyperoxalurias: Best practices","volume":"39","author":"Michael","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/ckj\/sfab217","article-title":"Primary hyperoxaluria type 1: Pathophysiology and genetics","volume":"15","author":"Fargue","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-023-01987-1","article-title":"Lumasiran: A review in primary hyperoxaluria type 1","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gang, X., Liu, F., and Mao, J. (2022). Lumasiran for primary hyperoxaluria type 1: What we have learned?. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.1052625"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: First approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","article-title":"Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: Design, development, and clinical studies","volume":"5","author":"Liu","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/fmc.13.151","article-title":"Small-molecule inhibitors of human LDH5","volume":"5","author":"Granchi","year":"2013","journal-title":"Future Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4155\/fmc.13.206","article-title":"Inhibition of lactate dehydrogenase activity as an approach to cancer therapy","volume":"6","author":"Fiume","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10545-017-0045-3","article-title":"Molecular therapy of primary hyperoxaluria","volume":"40","author":"Torres","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Moya-Garzon, M.D., Gomez-Vidal, J.A., Alejo-Armijo, A., Altarejos, J., Rodriguez-Madoz, J.R., Fernandes, M.X., Salido, E., Salido, S., and Diaz-Gavilan, M. (2021). Small molecule-based enzyme inhibitors in the treatment of primary hyperoxalurias. J. Pers. Med., 11.","DOI":"10.3390\/jpm11020074"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.aaa1299","article-title":"Targeting LDH enzymes with a stiripentol analog to treat epilepsy","volume":"347","author":"Sada","year":"2015","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","article-title":"Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning","volume":"129","author":"Huguet","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40620-021-01116-9","article-title":"Treatment with stiripentol in a patient with primary hyperoxaluria type 1: Lesson for the clinical nephrologist","volume":"35","author":"Violier","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","article-title":"Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient","volume":"35","author":"Kempf","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfaa068","article-title":"Is stiripentol truly effective for treating primary hyperoxaluria?","volume":"14","author":"Hoppe","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Huang, Y., Zhu, W., Zhou, J., Huang, Q., and Zeng, G. (2024). Navigating the evolving landscape of primary hyperoxaluria: Traditional management defied by the rise of novel molecular drugs. Biomolecules, 14.","DOI":"10.3390\/biom14050511"},{"key":"ref_30","unstructured":"Clinical Trials, National Library of Medicine, National Center for Biotechnology Information (2024, October 31). Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older with Primary Hyperoxaluria Type 1, 2 or 3 (CRYSTAL), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06465472?cond=hyperoxaluria&term=stiripentol&rank=2."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1016\/j.ekir.2024.08.031","article-title":"Opportunities in primary and enteric hyperoxaluria at the cross-roads between the clinic and laboratory","volume":"9","author":"Cellini","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12996","DOI":"10.1021\/jacs.2c05486","article-title":"Reactive dicarbon as a flexible ligand for transition-metal coordination and catalysis","volume":"144","author":"Wu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Diaz, I., Salido, S., Nogueras, M., and Cobo, J. (2022). Design and synthesis of new pyrimidine-quinolone hybrids as novel hLDHA inhibitors. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070792"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Alejo-Armijo, A., Cuadrado, C., Altarejos, J., Fernandes, M.X., Salido, E., Diaz-Gavilan, M., and Salido, S. (2022). Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias. Bioorg. Chem., 129.","DOI":"10.1016\/j.bioorg.2022.106127"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"122224","DOI":"10.1016\/j.ijpharm.2022.122224","article-title":"Chitosan derivatives as nanocarriers for hLDHA inhibitors delivery to hepatic cells: A selective strategy for targeting primary hyperoxaluria diseases","volume":"627","author":"Salido","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ortega-Vidal, J., Ruiz-Martos, L., Salido, S., and Altarejos, J. (2023). Proanthocyanidins in pruning wood extracts of four European plum (Prunus domestica L.) cultivars and their hLDHA inhibitory activity. Chem. Biodivers., 20.","DOI":"10.1002\/cbdv.202200931"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Salido, S., Alejo-Armijo, A., and Altarejos, J. (2023). Synthesis and hLDH inhibitory activity of analogues to natural products with 2,8-dioxabicyclo[3.3.1]nonane scaffold. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129925"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Diaz, I., Salido, S., Nogueras, M., and Cobo, J. (2024). Synthesis of ethyl pyrimidine-quinolincarboxylates selected from virtual screening as enhanced lactate dehydrogenase (LDH) inhibitors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179744"},{"key":"ref_39","first-page":"39503","article-title":"Tracking selective internalization and intracellular dynamics of modified chitosan polymeric micelles of interest in primary hyperoxaluria diseases","volume":"9","author":"Salido","year":"2024","journal-title":"ACS Omega"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1172\/JCI128709","article-title":"Lactate dehydrogenase 5: Identification of a druggable target to reduce oxaluria","volume":"129","author":"Stevens","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114396","DOI":"10.1016\/j.ejmech.2022.114396","article-title":"New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production","volume":"237","author":"Fernandes","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/13543776.2024.2412575","article-title":"A patent review of lactate dehydrogenase inhibitors (2014-present)","volume":"34","author":"Bononi","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.jmedchem.5b00168","article-title":"Recent update on human lactate dehydrogenase enzyme 5 (hLDH5) inhibitors: A promising approach for cancer chemotherapy","volume":"59","author":"Rani","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4155\/fmc-2019-0287","article-title":"Structural and functional regulation of lactate dehydrogenase-A in cancer","volume":"12","author":"Woodford","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Han, J.H., Lee, E.-J., Park, W., Ha, K.-T., and Chung, H.-S. (2023). Natural compounds as lactate dehydrogenase inhibitors: Potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1275000"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.molstruc.2018.11.088","article-title":"Spectroscopic identification, structural features, Hirshfeld surface analysis and molecular docking studies on stiripentol: An orphan antiepileptic drug","volume":"1180","author":"Almutairi","year":"2019","journal-title":"J. Mol. Struct."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1055\/s-2007-983746","article-title":"Simple and effective protocol for Claisen-Schmidt condensation of hindered cyclic ketones with aromatic aldehydes","volume":"2007","author":"Vashchenko","year":"2007","journal-title":"Synthesis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/1099-0690(200107)2001:13<2435::AID-EJOC2435>3.0.CO;2-0","article-title":"Copper-catalysed asymmetric 1,4-addition of organozinc compounds to linear aliphatic enones using 2,2\u2032-dihydroxy 3,3\u2032-dithioether derivatives of 1,1\u2032-binaphthalene","volume":"13","author":"Borner","year":"2001","journal-title":"Eur. J. Org. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0920-1211(92)90088-B","article-title":"Comparative anticonvulsant potency and pharmacokinetics of (+)- and (-)-enantiomers of stiripentol","volume":"12","author":"Shen","year":"1992","journal-title":"Epilepsy Res."},{"key":"ref_50","first-page":"544","article-title":"Metabolic chiral inversion of stiripentol in the rat. I. Mechanistic studies","volume":"22","author":"Zhang","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"ref_51","first-page":"7","article-title":"Lipase catalysed kinetic resolution of stiripentol","volume":"4","author":"Jacobsen","year":"2012","journal-title":"Int. J. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tetasy.2013.02.006","article-title":"Synthesis of the antiepileptic (R)-stiripentol by a combination of lipase catalyzed resolution and alkene metathesis","volume":"24","author":"Sundby","year":"2013","journal-title":"Tetrahedron Asymmetry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10337-014-2818-2","article-title":"Analysis of stiripentol enantiomers on several chiral stationary phases: A comparative study","volume":"78","author":"Saleh","year":"2015","journal-title":"Chromatographia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/jo991498u","article-title":"Application of the Russig-Laatsch reaction to synthesize a bis[5]helicene chiral pocket for asymmetric catalysis","volume":"65","author":"Dreher","year":"2000","journal-title":"J. Org. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11192","DOI":"10.1016\/j.tet.2005.09.023","article-title":"Enantiospecific synthesis, separation and olfactory evaluation of all diastereomers of a homologue of the sandalwood odorant Polysantol\u00ae","volume":"61","author":"Castro","year":"2005","journal-title":"Tetrahedron"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1246\/cl.1995.513","article-title":"Application of modified Mosher\u2019s method to \u03b1-aromatic secondary alcohols. Exception of the rule and conformational analyses","volume":"24","author":"Ohtani","year":"1995","journal-title":"Chem. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cass, Q., Tiritan, M.E., Junior, J.M.B., and Barreiro, J.C. (2023). Absolute configuration from chiroptical spectroscopy. Chiral Separations and Stereochemical Elucidation. Fundamentals, Methods, and Applications, Wiley.","DOI":"10.1002\/9781119802280"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.phytochem.2015.03.007","article-title":"Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase","volume":"116","author":"Bader","year":"2015","journal-title":"Phytochemistry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"107832","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/taap.2000.9091","article-title":"Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat","volume":"170","author":"Tran","year":"2001","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"110073","DOI":"10.1016\/j.yebeh.2024.110073","article-title":"Adverse events associated with stiripentol in children aged 0\u201317 years: An analysis of a real-world pharmacovigilance database","volume":"161","author":"Chen","year":"2024","journal-title":"Epilepsy Behav."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Armarego, W.L.F. (2017). Purification of Laboratory Chemicals, Butterworth-Heinemann. [8th ed.].","DOI":"10.1016\/B978-0-12-805457-4.50003-3"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/nprot.2007.354","article-title":"Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons","volume":"2","author":"Hoye","year":"2007","journal-title":"Nat. Protoc."},{"key":"ref_64","unstructured":"Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Petersson, G.A., and Nakatsuji, H. (2024, November 06). Gaussian 16 Rev. C.02, Wallingford, CT. Available online: https:\/\/gaussian.com\/g16new\/."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1021\/cr9904009","article-title":"Quantum mechanical continuum solvation models","volume":"105","author":"Tomasi","year":"2005","journal-title":"Chem. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/chir.22138","article-title":"SpecDis: Quantifying the comparison of calculated and experimental electronic circular dichroism spectra","volume":"25","author":"Bruhn","year":"2013","journal-title":"Chirality"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.06.028","article-title":"Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors","volume":"101","author":"Rupiani","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2049-3002-1-19","article-title":"Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells","volume":"1","author":"Billiard","year":"2013","journal-title":"Cancer Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:47Z","timestamp":1760115107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":68,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252413266"],"URL":"https:\/\/doi.org\/10.3390\/ijms252413266","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}